UPDATE: Needham & Company Upgrades Acadia Pharmaceuticals (ACAD) to Buy, $9 Price Target
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall St starts the month strong as Mideast deal hopes rise
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Acadia Pharma (ACAD) Met Primary Endpoint in Pimavanserin Phase III
November 27, 2012 7:27 AM ESTAcadia Pharmaceuticals, Inc. (NASDAQ: ACAD) announced successful top-line results from its pivotal Phase III trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinsons disease psychosis (PDP). Pimavanserin is ACADIAs proprietary, non-dopaminergic product candidate that selectively blocks serotonin 5-HT2A receptors. Pimavanserin met the primary endpoint in the Phase III trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale (p=0.001). Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinsons Disease Rating Scale,... More
Acadia Pharma (ACAD) Halted Ahead of Pivotal Pimavanser Phase III Presentation
November 27, 2012 7:25 AM ESTAcadia Pharmaceuticals, Inc. (NASDAQ: ACAD) shares are halted Tuesday morning ahead of the company's conference call and webcast to present the top-line results from its pivotal Phase III trial with pimavanserin in patients with Parkinsons disease psychosis (PDP).
The... More
Acadia Pharmaceuticals (ACAD) Jumps Ahead of Data Presentation
November 26, 2012 5:47 PM ESTShares of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) are up 6.5 percent after-hours Monday after the company announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, November 27, 2012 to present the top-line results from its pivotal Phase III trial with... More
